Login
$LFMD
$1.82 -$0.03 (1.62%) After hours

$LFMD 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +3 more

Third quarter 2026 revenue of $44.6 million; adjusted EBITDA loss of approximately $0.4 million, within the Company’s guidance range of negative $1 million to positive $2 million.

15 Sep 2026 8-K: Regulation FD Disclosure

Through an exclusive collaboration with LifeMD, eligible AT&T wireless and fiber customers receive a complimentary LifeMD membership, a $228 annual value, with on-demand access to a nationwide virtual care and pharmacy platform.

05 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.

22 Jun 2026 8-K: Regulation FD Disclosure

LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

06 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

First quarter 2026 revenue of $50.2 million and adjusted EBITDA loss of $4.5 million, above and in line, respectively, with the Company’s guidance.

18 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

This EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of March 16, 2026 (the “Effective Date”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), having corporate headquarters at 236 Fifth Avenue, Suite 400, New...

09 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million.

06 Jan 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

CREDIT AGREEMENT, dated as of January 2, 2026, between LIFEMD, INC., a Delaware corporation (the “Borrower”), and CITIZENS BANK, N.A. (the “Lender”).

17 Nov 2025 8-K: Results of Operations and Financial Condition

Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million.

05 Nov 2025 8-K: Regulation FD Disclosure

NEW YORK, November 5, 2025 — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quarter 2025 earnings release and conference call to Mon...

04 Nov 2025 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more

THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of November 4, 2025, is entered into by and among WorkSimpli Software LLC, a Puerto Rico limited liability company (the “Company”), LifeMD, Inc., a Delaware corporation (“LifeMD”...

21 Aug 2025 8-K: Changes in Registrant's Certifying Accountant

We have read the statements made by LifeMD, Inc. under Item 4.01 of its Form 8-K dated August 21, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statement...

05 Aug 2025 8-K: Results of Operations and Financial Condition

Total revenue increased 23% year-over-year to $62.2 million; adjusted EBITDA rose 223% to $7.1 million

31 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

THIS SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “Second Amendment”) is entered into as of May 7, 2024 (the “Second Amendment Effective Date”) by and between Shayna Dray, an individual and resident of the State of Rhode Island, (t...

16 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 13, 2025, LifeMD, Inc. (the “Company”) held an annual meeting of stockholders (the “Annual Meeting”). A majority in interest of all stock issued, outstanding and entitled to vote at the Annual Meeting were present in person or by...

06 May 2025 8-K: Results of Operations and Financial Condition

Total revenues increased 49% year-over-year to $65.7 million with telehealth revenue up 70%

29 Apr 2025 8-K: Regulation FD Disclosure

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the acquisition of key assets from Optimal Human Health MD (“Optimal”), a nationwide women’s he...

25 Apr 2025 8-K: Changes in Registrant's Certifying Accountant

We have read the statements made by LifeMD, Inc. under Item 4.01 of its Form 8-K dated April 24, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements...

10 Mar 2025 8-K: Results of Operations and Financial Condition

Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60%

31 Dec 2024 8-K: Departure/Election of Directors or Officers; Compensation

THIS SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “Second Amendment”) is entered into as of December 24, 2024 (the “Second Amendment Effective Date”) by and between Justin Schreiber, an individual and resident of the State of Penns...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support